Tratamiento adyuvante en cáncer de colon: Nuestra experiencia

colon cancer is one of the most common tumors in our country. following surgery, adjuvant chemotherapy has shown benefit for patients at high risk and node-positive, so it is considered standard modality. objective: the aim of this study is to evaluate the experience of our institution as far as this treatment modality, referred for five years. results: preliminarily we evaluated total of 118 patients, the gender distribution was equal. left colon tumors, occupied the highest percentage (45.76 %) and the most common histology was adenocarcinoma. with regard to tnm, t3 was the most frequent (53.1 %) and n0 also (46.9 %). of the sample assessed, 63.2 % received adjuvant chemotherapy, being the most widely used schemes, folfox 4 62.5 %, xelox 18.1 % and capecitabine 13.9 %. 66.7 % of patients had adverse events, being the most frequent diarrhea, nausea, vomiting, and peripheral neuropathy, all g1/2 in most cases. there were no treatment-related deaths. 100 % of patients had follow-up, for the year 2009, 55.93 % of them were alive. the os was greater in the group that received adjuvant treatment with regard to that it did not receive it, without statistics significant (p=0.098) since up to the date there has not been reached the median of global survival. conclusions: similar results were obtained with regard to the dfs, being this major in the group that received chemotherapy, versus the group that did not receive it, reached significant statistics (p=0.045).